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Introduction
Lung cancer is the leading cause of cancer death worldwide. Fusion of the echinoderm microtubule-associated protein-like 4 gene (EML4) with the anaplastic lymphoma kinase gene (ALK), which results in the production of a fusion protein (EML4-ALK), occurs in 5 to 10% of cases of non-small cell lung cancer (NSCLC) (1) (2) (3) . This transforming fusion leads to activation of downstream signaling molecules, and inhibition of ALK signaling has shown marked antitumor effects in NSCLC positive for EML4-ALK in both preclinical and clinical studies (4) . Despite their initial response, however, individuals with EML4-ALK-positive NSCLC treated with ALK inhibitors eventually acquire resistance to these drugs (5) , and the molecular mechanisms responsible for such resistance remain largely uncharacterized. With the use of an in vitro cell model and cells newly derived from a patient with acquired resistance to the ALK inhibitor crizotinib, we have now uncovered a previously unknown mechanism of such resistance.
Materials and Methods

Cell culture and reagents
The H3122 human NSCLC cell line was obtained as previously described (6) , and H1299 human NSCLC cells were obtained from American Type Culture Collection (Manassas, VA). Tanizaki et al. 5 The cells were maintained under a humidified atmosphere of 5% CO 2 at 37°C in RPMI 1640 medium (Sigma, St. Louis, MO), which contains no biological ligands including EGF, supplemented with 10% FBS. TAE684, crizotinib, and BIBW2992 were obtained from ShangHai Biochempartner (Shanghai, China). Paclitaxel was from Sigma, and adriamycin was from Wako (Osaka, Japan). Recombinant human epidermal growth factor (EGF) was from R&D Systems (Minneapolis, MN).
Generation of TAE684-resistant H3122 cells
H3122 cells were initially exposed to 0.01 μM TAE684. They were then isolated by limiting dilution, maintained, and passaged normally with gradually increasing doses of TAE684, up to a maximum of 1 μM. The established resistant cell lines, designated H3122/TR1 and H3122/TR2, were maintained in medium containing the maximal dose of TAE684 (1 μM) in order to maintain selective pressure for TAE684 resistance.
Growth inhibition assay in vitro
Cell viability was assessed with an MTT assay as previously described (7) .
Annexin V binding assay
Binding of annexin V to cells was measured with the use of an Annexin-V-FLUOS Staining Kit (Roche, Basel, Switzerland), as previously described (7) .
Immunoblot analysis
Immunoblot analysis was performed as previously described (7) . Rabbit polyclonal antibodies Tanizaki et al. 6 to phosphorylated human ALK (pY1608), to ALK, to the phosphorylated EGF receptor (pY1068), to phosphorylated HER2 (pY1221), to phosphorylated HER3 (pY1289), to phosphorylated AKT, to AKT, to phosphorylated STAT3, and to STAT3 were obtained from Cell Signaling Technology (Danvers, MA); those to HER3, to extracellular signal-regulated kinase (ERK), and to phosphorylated ERK were from Santa Cruz Biotechnology (Santa Cruz, CA); those to HER2 were from Millipore (Billerica, MA); and those to β-actin were from Sigma. Mouse monoclonal antibodies to the EGF receptor (EGFR) were obtained from Invitrogen (Tokyo, Japan).
RT and real-time PCR analysis
Total RNA was extracted from cells with the use of an RNeasy Mini Kit (Qiagen, Germantown, (5 -AGAGTTGAACAGGTAGTTAAGCCCC-3 , 5 -GTCGAAGTTTCTTTCGTTCCTCAG-3 ). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was used as an internal standard.
ELISA for ligands
The concentrations of EGF, TGF-α, and amphiregulin in conditioned medium were determined as previously described (8), with the use of a Human Quantikine ELISA Kit (R&D Systems). 
Isolation
Results
Generation of ALK inhibitor-resistant lines from EML4-ALK-positive H3122 cells
The NSCLC cell line H3122 expresses EML4-ALK and is highly sensitive to the ALK tyrosine kinase inhibitor (TKI) TAE684. We generated TAE684-resistant H3122 cell lines (H3122/TR1 and H3122/TR2) by exposing the parental cells to increasing concentrations of TAE684. Short Fig. 1A ). The H3122/TR cells were also resistant to crizotinib, another ALK-targeted TKI, but not to other drugs including paclitaxel and adriamycin (Table 1 , Fig. 1A , and data not shown). TAE684 also induced a marked increase in the level of apoptosis in H3122 cells, whereas it had no such effect in H3122/TR cells (Fig. 1B) . Collectively, these data suggested that H3122/TR cells had acquired resistance specific to ALK inhibitors.
Activation of alternative signaling pathways in H3122/TR cells
We next investigated the mechanism responsible for resistance to ALK-TKIs in H3122/TR cells. Immunoblot analysis revealed that the abundance of EML4-ALK was reduced in both H3122/TR cell lines compared with that in H3122 cells ( Fig. 2A) . Quantitative RT-PCR analysis showed that the amount of EML4-ALK mRNA was also reduced markedly in H3122/TR cells relative to that in the parental cells ( Supplementary Fig. 1 ), suggesting that the down-regulation of EML4-ALK expression is mediated at the transcriptional level. We did not detect any secondary mutations of ALK in H3122/TR cells (data not shown), with such mutations having previously been shown to give rise to ALK-TKI resistance (5, 9, 10). TAE684 inhibited the phosphorylation of ERK and STAT3 in H3122 cells, but had no such effects in H3122/TR cells ( Fig. 2A) . Given that signaling via ERK and STAT3 is maintained in H3122/TR cells in the presence of TAE684, we investigated whether alternative upstream pathways are activated in these cells. We found that the level of EGFR phosphorylation was increased in the resistant cells compared with the parental cells, although the abundance of EGFR was decreased in the former cells (Fig. 2B) . Phosphorylation of the EGFR-related proteins HER2 and HER3 was also increased in both H3122/TR cell lines (Fig. 2B) . To investigate the mechanism responsible for activation of these receptor tyrosine kinases in H3122/TR cells, we examined the expression of ligands for HER family proteins, including EGF, TGF-α, and amphiregulin. Quantitative RT-PCR analysis revealed that the amount of EGF mRNA, but not that of TGF-α or amphiregulin mRNAs, was greatly increased in H3122/TR cells compared with that in parental H3122 cells (Fig. 2C) . Consistent with these results, ELISA showed that secretion of EGF, but not that of TGF-α or amphiregulin, was increased in H3122/TR cells (Fig. 2D) . We next examined the effect of an EGFR-TKI on apoptosis in the parental and resistant cell lines. Treatment with BIBW2992, an irreversible TKI for EGFR, induced apoptosis in H3122/TR cells, but not in H3122 cells (Fig. 2E) .
Furthermore, the extent of apoptosis induced by the combination of TAE684 and BIBW2992 in H3122/TR cells was significantly greater than that induced by BIBW2992 alone (Fig. 2E) . 
EGF activates HER family signaling and induces TAE684 resistance in parental H3122 cells
To investigate whether EGF secretion plays a role in ALK-TKI resistance, we examined the effect of exogenous EGF on ALK-TKI sensitivity in H3122 cells. We found that exposure to EGF induces resistance to TAE684 in these cells (Fig. 3A) , supporting the notion that increased secretion of this ligand can lead to the development of ALK-TKI resistance. TAE684 inhibited EML4-ALK phosphorylation in H3122 cells in the absence or presence of EGF stimulation, whereas it failed to inhibit downstream signaling including the phosphorylation of ERK and STAT3 in the presence of EGF (Fig. 3B) . EGF increased the levels of EGFR, HER2, and HER3 phosphorylation in H3122 cells (Fig. 3C) . These data suggested that EGF-induced activation of EGFR, HER2, and HER3 might underlie resistance to ALK inhibitors in H3122/TR cells.
Isolation of drug-sensitive revertants from ALK-TKI-resistant cells
We cultured H3122/TR1 cells continuously in the absence of TAE684 for >2 months and thereby obtained H3122/TR revertant (H3122/TR rev) cells that had regained sensitivity to TAE684 (Fig. 4A) . RT-PCR analysis and ELISA revealed that both the amount of EGF mRNA and the extent of EGF secretion in H3122/TR rev cells had been restored to levels similar to those in parental H3122 cells (Fig. 4B) . This reduced level of EGF expression in H3122/TR rev cells compared with that in H3122/TR1 cells was accompanied by down-regulation of EGFR, HER2, and HER3 phosphorylation as well as by up-regulation of both the abundance and phosphorylation of EML4-ALK (Fig. 4C) . These data suggested that down-regulation of EML4-ALK expression and activation of HER family proteins, and the associated shift in signal transduction from the ALK signaling pathway to HER family pathways, are responsible for the acquired resistance to ALK inhibitors in H3122/TR cells.
Establishment of an ALK-TKI-resistant cell line from a clinical specimen
We established a cell line, designated K-3, from the pleural effusion of a patient with EML4-ALK-positive lung cancer who had developed clinical resistance to crizotinib after treatment for 6 months. The K-3 cells were found to be resistant to both crizotinib and TAE684, with IC 50 values of 3.25 and 5.96 μM, respectively (Fig. 5A) . We did not detect any secondary mutations of ALK in K-3 cells. On the other hand, similar to the results obtained with H3122/TR cells, the abundance of EGF mRNA and the extent of EGF secretion were both markedly increased in K-3 cells compared with those in H3122 cells (Fig. 5B) . Furthermore, immunoblot analysis showed that the level of EML4-ALK phosphorylation was decreased in K-3 cells, whereas that of EGFR, HER2, and HER3 phosphorylation was increased (Fig. 5C ). antitumor effects in such tumors (3, 11, 12) . However, acquired resistance to ALK inhibitors has already been found to limit the therapeutic potential of these agents (5, 10, 13) 
manifested EGF-mediated HER family activation. Consistent with our results, amphiregulin-mediated EGFR activation was recently shown to be associated with resistance to ALK inhibitors (9, 14) . Collectively, these data suggest that ligand-activated HER family signaling gives rise to ALK-TKI resistance. We and others have shown that ligand-mediated signaling pathway activation accompanied by up-regulation of ligand mRNA is associated with resistance to molecularly targeted therapy in several cancer models (9, 15) . In the present study, we found that the abundance of EGF mRNA is increased in H3122/TR cells. Given that the EGF gene contains consensus binding sequences for many transcription factors, including NF-κB, AP-1, AP-2, AP-3, and SP1 (16), such factors may play a role in the up-regulation of EGF expression observed in our study.
In the present study, we found that, in the absence of ALK inhibition, activation of EGFR, HER2, and HER3 in H3122/TR cells becomes down-regulated in association with a reversion to TAE684 sensitivity. Consistent with these results, termination of treatment with an EGFR inhibitor after the development of drug resistance in EGFR mutation-positive NSCLC resulted in the loss of the resistance-associated mutation (T790M) and restoration of tumor sensitivity to treatment with EGFR inhibitors in both preclinical and clinical settings (17-19).
Our observations now suggest that the development of resistance to ALK inhibitors is potentially reversible. They provide a rationale for temporary cessation of treatment after the development of ALK-TKI resistance in patients with EML4-ALK-positive lung cancer in C, H3122 cells were incubated with or without EGF (100 ng/ml) for 6 h, after which cell lysates were prepared and subjected to immunoblot analysis. Figure 2C (left panel). Culture supernatants were also assayed for EGF by ELISA as in Figure   2D (right panel). All data are expressed relative to the corresponding value for H3122 cells and are means ± SE from three independent experiments. C, Cells were deprived of serum for 24 h, after which cell lysates were prepared and subjected to immunoblot analysis with antibodies to the indicated proteins. 
